Delivery Order SPE2DB20D3103-SPE2DB25FP8Z5
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,109.65 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. Awarded on August 11, 2025, with completion expected by August 12, 2025, this firm fixed-price delivery order carries no set-aside designation and represents a competitively awarded contract. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $4,013.94 to AmerisourceBergen Drug Corp for 90-count tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. Awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, this firm fixed-price contract utilized competitive procedures with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a $38,869.51 delivery order to AmerisourceBergen Drug Corp for 90-count tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. This firm fixed-price, competitively awarded delivery order is scheduled for completion by July 28, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award carries no set-aside designation and represents a routine pharmaceutical procurement through the federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $20,957.72 to AmerisourceBergen Drug Corp for the supply of MYRBETRIQ ER 50 mg tablets (90-count units). This competitive award, issued on August 15, 2025, with an ultimate completion date of August 18, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $2,729.22 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (30-count supply). This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 1, 2025, and represents a competitively awarded transaction under AmerisourceBergen's broader pharmaceutical supply relationships with the federal government. The place of performance is AmerisourceBergen's corporate office...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $28,170.24 by the Defense Logistics Agency (DLA) for the supply of Myrbetriq ER 50 mg tablets (90-count units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 1, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $11,783.17 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a potential value of $999,999,999.00 and extends through December 2026....
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $29,045.67 to AmerisourceBergen Drug Corp for Myrbetriq ER 50 mg tablets (90-count supply) on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a primary...
- The Defense Logistics Agency awarded a $3,853.29 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for Myrbetriq ER 50 mg tablets (90-count supply). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 12, 2025. The contract is performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, and represents a child delivery order under a larger contract vehicle. This delivery...
- The Defense Logistics Agency awarded a $8,062.00 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This is a firm fixed-price delivery order with no set-aside designation, utilizing open competition. The contract is set to complete on August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP8Z5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,157.53 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. This competitively awarded, non-set-aside delivery order was issued on August 15, 2025, with an ultimate completion date of August 18, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with firm fixed pricing terms. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical prime vendor for federal medical procurement, supplying a comprehensive portfolio of pharmaceutical products and medical supplies to support military and veteran healthcare systems worldwide. The company's role under the DLA Medical Supply Chain demonstrates its capacity to fulfill diverse pharmaceutical requirements across multiple therapeutic domains for Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 8/15/25 |